Studies on a biological response modifying LYSAT from Propionibacterium avidum KP 40.
Propionibacterium avidum KP 40 cells were mechanically disintegrated in order to obtain the soluble immunostimulatory (antineoplastic) LYSAT. Chemiluminescence measurements of human leukocyte function yielded enhanced activation of the cells after incubation with 2.5 and 5 mg of LYSAT. As compared to non-treated controls, administration of LYSAT to BALB/c-mice (1, 2.5 and 5 mg; intraperitoneally, subcutaneously, intranasal; 7, 4 and 2 days prior to challenge) induced a significant enlargement of the spleen as well as significantly reduced sarcoma L-1 lung colonization 14 days after challenge and evidently enhanced chemiluminescence response of peritoneal macrophages.
Pulverer
G
G
Hygiene-Institut, Universität Köln.
Ko
H L
HL
Beuth
J
J
Roszkowski
K
K
Roszkowski
W
W
Jeljaszewicz
J
J
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002634:Chemotaxis, Leukocyte; D007700:Kinetics; D008163:Luminescent Measurements; D008175:Lung Neoplasms / Q000628:therapy*; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D010586:Phagocytes / Q000276:immunology*; D011424:Propionibacterium / Q000276:immunology*; D012513:Sarcoma, Experimental / Q000628:therapy*; D013154:Spleen / Q000276:immunology
D000276:Adjuvants, Immunologic